Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | +25.56% | +21.01% | -15.23% |
May. 28 | Ikena Oncology to Cut Jobs, Explore Options, End IK-930 Program; Shares Rise After Hours | MT |
May. 13 | Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 7M | Sales 2025 * | 8.5M | Capitalization | 64.18M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -74M | EV / Sales 2024 * | 9.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.55 x |
P/E ratio 2024 * |
-1.39
x | P/E ratio 2025 * |
-1.04
x | Employees | 34 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93% |
1 week | -3.62% | ||
Current month | +0.76% | ||
1 month | +2.31% | ||
3 months | -11.92% | ||
6 months | -7.64% | ||
Current year | -32.49% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Manfredi
FOU | Founder | 53 | 16-01-31 |
Jotin Marango
DFI | Director of Finance/CFO | 45 | 22-04-24 |
Caroline Germa
CTO | Chief Tech/Sci/R&D Officer | 52 | Feb. 28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 16-02-29 | |
David Bonita
BRD | Director/Board Member | 48 | 15-12-31 |
Director/Board Member | 55 | 20-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +4.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 1.67 | +25.56% | 3,361,796 |
24-05-28 | 1.33 | 0.00% | 1,530,787 |
24-05-24 | 1.33 | +3.91% | 146,065 |
24-05-23 | 1.28 | -5.19% | 137,391 |
24-05-22 | 1.35 | -2.17% | 93,290 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.49% | 64.18M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- IKNA Stock